Suspension of trading

News Durect

Stocks

DRRX

US2666055007

Delayed Nasdaq Other stock markets 16:00:00 2025-09-10 EDT			5-day change	1st Jan Change
1.910 ^USD	-1.04%		-.--%	-

25-09-11	Bausch Health Companies Inc. completed the acquisition of DURECT Corporation.	CI
25-09-11	Bausch Health Completes US$63 Million Durect Acquisition, Adds Breakthrough Hepatitis Therapy to Pipeline	MT

All News

Mentions Relevance

25-09-11	Bausch Health Companies Inc. completed the acquisition of DURECT Corporation.	CI
25-09-11	Durect Corporation Announces Board Changes	CI
25-09-11	Bausch Health Completes $63 Million Acquisition of Durect	MT
25-09-10	DURECT Corporation(NasdaqCM:DRRX) dropped from S&P TMI Index	CI
25-09-10	DURECT Corporation(NasdaqCM:DRRX) dropped from NASDAQ Composite Index	CI
25-08-26	Bausch Health Extends Tender Offer for DURECT Shares to Sept. 10	MT
25-08-22	Durect Insider Bought Shares Worth $386,666, According to a Recent SEC Filing	MT
25-08-12	Durect: Q2 Earnings Snapshot	AQ
25-08-12	DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health	PR
25-08-12	DURECT Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
25-08-08	Durect Bausch Health extend tender offer date to Aug 12 - SEC filing	RE
25-07-29	Northland Downgrades DURECT to Market Perform From Outperform, Price Target is $2.50	MT
25-07-29	Bausch Health to Acquire Durect for $63 Million	MT
25-05-14	Durect: Q1 Earnings Snapshot	AQ
25-05-13	DURECT Corporation Reports First Quarter 2025 Financial Results And Provides Business Update	RE
25-05-13	DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update	PR
25-05-13	DURECT Corporation Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-26	DURECT Corporation Auditor Raises 'Going Concern' Doubt	CI
25-03-26	DURECT Corporation, Q4 2024 Earnings Call, Mar 26, 2025
25-03-26	Durect: Q4 Earnings Snapshot	AQ
25-03-26	DURECT Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
25-03-19	DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update	PR
25-02-21	DURECT Corporation Announces Retirement of Terrence F. Blaschke as Board of Director, Member of the Nominating and Corporate Governance Committee	CI
25-02-04	DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference	PR
25-01-28	DURECT Corporation Announces Publication of Larsucosterol Phase 2B Results in NEJM Evidence	CI